发明授权
US08809264B2 Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors
有权
喹喔啉基大环丙型肝炎病毒丝氨酸蛋白酶抑制剂
- 专利标题： Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors
- 专利标题（中）： 喹喔啉基大环丙型肝炎病毒丝氨酸蛋白酶抑制剂
-
申请号： US11768723申请日： 2007-06-26
-
公开(公告)号： US08809264B2公开(公告)日： 2014-08-19
- 发明人: Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
- 申请人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
- 申请人地址： US MA Watertown
- 专利权人： Enanta Pharmaceuticals, Inc.
- 当前专利权人： Enanta Pharmaceuticals, Inc.
- 当前专利权人地址： US MA Watertown
- 代理机构： Edwards Wildman Palmer LLP
- 代理商 Jeffrey D. Hsi; Stephen W. Rafferty
- 主分类号： A61K38/00
- IPC分类号： A61K38/00 ; C07D245/04 ; A61K38/21 ; C07D403/12
摘要：
The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
公开/授权文献
信息查询
IPC分类:
